{"classes":[{"categories":[{"measurements":[{"comment":"The median and 90% CI were calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and were non estimable at the time of analysis as there was insufficient number of participants with the event of interest (less than 50% for the median estimate) occurred in the study.","groupId":"OG000","lowerLimit":"2.92","upperLimit":"NA","value":"4.47"},{"comment":"The median and 90% CI were calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and were non estimable at the time of analysis as there was insufficient number of participants with the event of interest (less than 50% for the median estimate) occurred in the study.","groupId":"OG001","lowerLimit":"2.30","upperLimit":"NA","value":"5.45"},{"comment":"The median and 90% CI were calculated with the Kaplan Meier process (a process in medical research to measure the proportion of participants surviving for a certain time after receiving treatment) and were non estimable at the time of analysis as there was insufficient number of participants with the event of interest (less than 50% for the median estimate) occurred in the study.","groupId":"OG002","lowerLimit":"0.95","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the start of treatment until death due to any cause.\n\nThis outcome measure was assessed only for substudy 1 Part A.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"AZD8853 3000 mg"}],"paramType":"MEDIAN","populationDescription":"Safety set included all participants who received any amount of IP.","reportingStatus":"POSTED","timeFrame":"First dose until study end (1 Year)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}